Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Reata Pharma (NQ: RETA ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Reata Pharma < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Why Avantor Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session July 28, 2023 Gainers Unique Fabricating, Inc. (NYSE: UFAB) shares jumped 113% to $0.4605 after gaining 12% on Thursday. Via Benzinga Biogen (NASDAQ: BIIB) Acquires Reata (NASDAQ: RETA) to Boost its Neurological Therapeutics Portfolio, Including SKYCLARYS® July 28, 2023 Reata's Acquisition to Propel Biogen's Growth Strategy Biogen Inc. (NASDAQ: BIIB) and Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have announced a Via Spotlight Growth Health Care Company Biogen Announces Acquisition of Reata Pharmaceuticals July 28, 2023 Via Benzinga Expert Ratings for Reata Pharmaceuticals July 24, 2023 Via Benzinga Reata Pharmaceuticals Inc. (NASDAQ: RETA) is a Stock Spotlight on 7/17 July 17, 2023 Via Investor Brand Network Dow Surges 250 Points; Exxon Mobil Earnings Miss Expectations July 28, 2023 U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 250 points on Friday. The Dow traded up 0.72% to 35,535.23 while the NASDAQ rose 1.89% to 14,316.53. The S&P 500,... Via Benzinga Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated July 28, 2023 Earlier today, Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of Via Benzinga Skechers, Chart Industries, Roku, Beazer Homes And Other Big Stocks Moving Higher On Friday July 28, 2023 U.S. stocks traded higher, with the Nasdaq Composite gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. Reata Pharmaceuticals, Inc. (NASDAQ: RETA) rose... Via Benzinga What 5 Analyst Ratings Have To Say About Reata Pharmaceuticals June 28, 2023 Via Benzinga What 4 Analyst Ratings Have To Say About Reata Pharmaceuticals June 12, 2023 Via Benzinga Why Is QuantumScape (QS) Stock Up 10% Today? July 28, 2023 QuantumScape (QS) stock is continuing to rally on Friday following an update from its latest earnings report and EV battery plans. Via InvestorPlace Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today? July 28, 2023 Reata Pharmaceuticals (RETA) stock is soaring higher on Friday as investors react to an acquisition deal with Biogen (BIIB). Via InvestorPlace Nasdaq Jumps 200 Points; Procter & Gamble Posts Upbeat Earnings July 28, 2023 U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 200 points on Friday. Following the market opening Friday, the Dow traded up 0.39% to 35,419.43 while the NASDAQ rose... Via Benzinga Biogen Announces $7.3 Billion Acquisition Of Reata Pharmaceuticals July 28, 2023 Reata stock surged more than 50% on the news. Via Investor's Business Daily Biogen Bolsters Rare Disease Portfolio, Agrees To Buy Reata Pharmaceuticals With Enterprise Value Of $7.3B July 28, 2023 Biogen Inc (NASDAQ: BIIB) has agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session July 28, 2023 Via Benzinga RETA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Reata Pharmaceuticals, Inc. Is Fair to Shareholders July 28, 2023 From Halper Sadeh LLC Via Business Wire Biogen to Acquire Reata Pharmaceuticals July 28, 2023 From Biogen Inc. Via GlobeNewswire 3 Top Biotech Stocks Defying the Bear Market July 13, 2023 Each has the potential to dramatically outperform the market. Via The Motley Fool Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023 July 06, 2023 Via Benzinga Stock Market Rally Roars Back Toward Highs; Carnival, Delta, Micron, Nvidia In Focus: Weekly Review June 30, 2023 Major indexes rebounded strongly and many stocks flashed buy signals. Via Investor's Business Daily Reata Surges 16% Over Three Days; CEO Reflects On The Tricky Path To Launch A First-Ever Drug June 29, 2023 The company can now launch its Friedreich's ataxia treatment, Skyclarys. Via Investor's Business Daily Reata Nears Breakout After Snagging FDA Blessing To Launch Its Friedreich's Ataxia Drug June 28, 2023 The company has now launched its treatment for Friedreich's ataxia, despite numerous obstacles. Via Investor's Business Daily Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday June 28, 2023 We're starting off Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on! Via InvestorPlace Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich’s Ataxia June 27, 2023 From Reata Pharmaceuticals, Inc. Via Business Wire Bragar Eagel & Squire, P.C. Is Investigating Reata, DLocal, Comerica, and Advance Auto Parts and Encourages Investors to Contact the Firm June 19, 2023 From Bragar Eagel & Squire Via GlobeNewswire Top 1% Biotech Stock Reata Pharmaceuticals Faces Another Hurdle June 16, 2023 Reata Pharmaceuticals took another step toward launching its highly anticipated drug, Skyclarys. Via Investor's Business Daily Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement June 15, 2023 From Reata Pharmaceuticals, Inc. Via Business Wire Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session June 15, 2023 Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396. Via Benzinga Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer June 13, 2023 From Reata Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.